For Medical Information requests, please contact:
Phone: 800-520-5568
Fax: 510-595-8183 Email:


Jazz Pharmaceuticals has an unwavering commitment to improving care for patients with serious medical conditions through innovative treatments. Our development pipeline projects currently include clinical development of new product candidates, line extensions for existing products and the generation of additional clinical data for existing products.


Updated 11/10/15

1 Evaluating in children and adolescents who have narcolepsy with cataplexy.
2 Hepatic veno-occlusive disease (VOD) with evidence of multi-organ dysfunction following hematopoietic stem cell transplantation.
3 Jazz Pharmaceuticals voluntarily suspended patient enrollment based on the occurrence of hypersensitivity-like reactions following the administration of JZP-416 in some treated patients. The company is in the process of collecting and evaluating the available data and plans to conduct additional research and analysis prior to determining whether to resume the study and determining next steps regarding the development of JZP-416.
EDS = Excessive Daytime Sleepiness, OSA = Obstructive Sleep Apnea, FDA = U.S. Food and Drug Administration, PDUFA = Prescription Drug User Fee Act, aGvHD = acute Graft vs Host Disease